结核病重组蛋白亚单位疫苗研究进展  

Research progress on recombinant protein subunit vaccine of tuberculosis

作　　者：曹倩倩 祝秉东[1] 牛红霞[1] CAO Qian-qian;ZHU Bing-dong;NIU Hong-xia(Institute of Pathogen Biology,School of Basic Medical Sciences,Lanzhou University,Lanzhou 730000,China)

机构地区：[1]兰州大学基础医学院病原生物学研究所,730000

出　　处：《中国防痨杂志》2021年第9期970-974,共5页Chinese Journal of Antituberculosis

基　　金：“十三五”国家科技重大专项(2018ZX10731301-004-004);国家自然科学基金青年基金(81701969)。

摘　　要：卡介苗是唯一应用于临床的结核病疫苗,但是其对成人结核病的保护效果仍存在不确定性。重组蛋白亚单位疫苗可提供长期的免疫保护效果,且成分明确、安全性好,因而具有较好的应用开发前景。作者对结核病重组蛋白亚单位疫苗的组分(结核分枝杆菌保护性抗原和免疫佐剂)、临床研究现况、应用策略及研究所面临的挑战等方面的进展进行了综述。Bacille Calmette-Guérin(BCG)is the only tuberculosis vaccine used clinically,but its protective effect against adult tuberculosis is still uncertain.Recombinant protein subunit vaccines can provide long-term immune protection,and have clear ingredients and good safety,so they have good prospects of application development.This article reviews the progress of the components of the tuberculosis recombinant protein subunit vaccine,including the protective antigens and adjuvants of Mycobacterium tuberculosis,the current status of clinical research,the application strategies and challenges faced by the research.

关 键 词：分枝杆菌 结核 疫苗 亚单位 重组蛋白质类 综述文献(主题) 

分 类 号：R392[医药卫生—免疫学]